Laurus Labs is currently trading at Rs. 399.00, up by 7.55 points or 1.93% from its previous closing of Rs. 391.45 on the BSE.
The scrip opened at Rs. 395.00 and has touched a high and low of Rs. 403.00 and Rs. 391.55 respectively. So far 12586 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 520.00 on 03-Apr-2018 and a 52 week low of Rs. 324.00 on 18-Feb-2019.
Last one week high and low of the scrip stood at Rs. 403.00 and Rs. 372.00 respectively. The current market cap of the company is Rs. 4204.25 crore.
The promoters holding in the company stood at 33.50%, while Institutions and Non-Institutions held 46.38% and 20.13% respectively.
Laurus Labs has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years. Through this long term agreement, the company will have the volume commitments from the Global Fund for the treatment of HIV/AIDS.
Under this Partnership agreement, the company received and executed the order from Global Fund which would cater to the supplies of the high burden diseases countries in Sub Saharan African (SSA) region. This is the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD) after the company received a tentative approval from USFDA in the month of February 2019.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |